Chris Shibutani
Stock Analyst at Goldman Sachs
(3.26)
# 962
Out of 4,847 analysts
99
Total ratings
51.92%
Success rate
1.45%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $34.65 | +188.60% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $1.45 | +107.61% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $7.00 | +114.29% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $31.27 | +2.33% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $115.64 | +18.47% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $11.20 | +194.77% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $324.20 | -6.85% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $33.29 | +53.20% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $154.42 | +0.38% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $5.12 | -21.88% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $9.44 | +111.86% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $750.78 | -3.70% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $22.90 | +13.54% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $125.00 | +22.40% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $187.25 | -7.61% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.75 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $48.09 | +43.48% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $20.60 | -36.89% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $40.58 | -43.32% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $1.99 | +2,412.56% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $43.58 | +19.32% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $23.35 | +156.96% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $8.27 | +117.65% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $3.24 | +424.69% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.45 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.93 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.33 | - | 4 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $29.65 | - | 3 | May 2, 2017 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $34.65
Upside: +188.60%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $1.45
Upside: +107.61%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $7.00
Upside: +114.29%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $31.27
Upside: +2.33%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $115.64
Upside: +18.47%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $11.20
Upside: +194.77%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $324.20
Upside: -6.85%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $33.29
Upside: +53.20%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $154.42
Upside: +0.38%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $5.12
Upside: -21.88%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $9.44
Upside: +111.86%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $750.78
Upside: -3.70%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $22.90
Upside: +13.54%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $125.00
Upside: +22.40%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $187.25
Upside: -7.61%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.75
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $48.09
Upside: +43.48%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $20.60
Upside: -36.89%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $40.58
Upside: -43.32%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $1.99
Upside: +2,412.56%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $43.58
Upside: +19.32%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $23.35
Upside: +156.96%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $8.27
Upside: +117.65%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $3.24
Upside: +424.69%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.45
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.93
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $3.33
Upside: -
May 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $29.65
Upside: -